Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T20796
(Former ID: TTDI01161)
|
|||||
| Target Name |
Reactive oxygen species (ROS)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Malaria [ICD-11: 1F40-1F45] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 1 Approved Drugs | + | ||||
| 1 | Tafenoquine | Drug Info | Approved | Plasmodium vivax malaria | [1] | |
| Clinical Trial Drug(s) | [+] 3 Clinical Trial Drugs | + | ||||
| 1 | Mitoquinone | Drug Info | Phase 2 | Hepatitis C virus infection | [2] | |
| 2 | Procysteine | Drug Info | Phase 2 | Amyotrophic lateral sclerosis | [3] | |
| 3 | Sodium pyruvate | Drug Info | Phase 1/2 | Asthma | [4] | |
| Mode of Action | [+] 3 Modes of Action | + | ||||
| Modulator | [+] 2 Modulator drugs | + | ||||
| 1 | Tafenoquine | Drug Info | [1] | |||
| 2 | Procysteine | Drug Info | [6] | |||
| Inhibitor | [+] 1 Inhibitor drugs | + | ||||
| 1 | Mitoquinone | Drug Info | [5] | |||
| Antagonist | [+] 1 Antagonist drugs | + | ||||
| 1 | Sodium pyruvate | Drug Info | [7] | |||
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Tafenoquine: First Global Approval.Drugs. 2018 Sep;78(14):1517-1523. | |||||
| REF 2 | ClinicalTrials.gov (NCT00433108) Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C. U.S. National Institutes of Health. | |||||
| REF 3 | ClinicalTrials.gov (NCT00002114) A Double-Blind, Randomized Parallel Group Study Comparing Procysteine to Placebo in HIV-Infected Patients Who Are Taking Antiretroviral Nucleosides. U.S. National Institutes of Health. | |||||
| REF 4 | ClinicalTrials.gov (NCT00262652) Safety and Efficacy Study of the Use of Sodium Pyruvate Bronchodilation in Asthmatics. U.S. National Institutes of Health. | |||||
| REF 5 | Mitoquinone (MitoQ) Inhibits Platelet Activation Steps by Reducing ROS Levels. Int J Mol Sci. 2020 Aug 27;21(17):6192. | |||||
| REF 6 | Protective effect of procysteine on Acinetobacter pneumonia in hyperoxic conditions. J Antimicrob Chemother. 2013 Oct;68(10):2305-10. | |||||
| REF 7 | A molecular mechanism of pyruvate protection against cytotoxicity of reactive oxygen species in osteoblasts. Mol Pharmacol. 2006 Sep;70(3):925-35. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.